MOR-106
Based on 1 Customer Validation
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis.
For research use only. We do not sell to patients.
- Purity: 97.42%
- CAS No.: 2304625-87-2
- Molecular Weight:144.02 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
|
NF-κB |
IL-17C |
MOR-106 (0.00001-1 nM, 30 min) potently blocks the interaction of human (IC50 = 59 pM) IL-17C and mouse (IC50 = 55 pM) IL-17C to IL-17RE[1].
MOR-106 (0.0001-1 μg/mL, 30 min) significantly inhibits IL-17C induced activation of NF-κB signaling pathway in NIH3T3 cells[1].
MOR-106 (0.001-1 μg/mL, 48 h) significantly inhibits the expression of DEFB4A and CSF3 induced by IL-17C and TNF-α in human and mouse primary keratinocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human and mouse primary keratinocytes
-
Concentration:0.001-1 μg/mL
-
Incubation Time:48 h
-
Result:Significantly reduced the levels of DEFB4A and CSF3.
MOR-106 (0.4-50 mg/kg, i.p., 3 days before, at the start, and 4 days after the first application of MC903) effectively alleviates MC903 induced atopic dermatitis and atopic eczema in female BALB/c mice[1][2].
MOR-106 (3 and 30 mg/kg, i.p., twice weekly, for 6 weeks) alleviates spontaneous atopic dermatitis in Flaky tail mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:IL-23 (1 μg, for 4 consecutive days) injeceted female BALB/c mice (8 weeks)[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), 3 days before and just before the first injection of IL-23
-
Result:Significantly reduced ear swelling and epidermal thickening.
Reduced the expression of inflammatory factors such as IL-17A, IL-22, IL-1β, LCN2, S100A8 and S100A9.
-
Animal Model:
-
Dosage:0.4, 2, 10 and 50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), 3 days before, at the start, and 4 days after the first application of MC903
-
Result:Dose dependently reduced ear swelling and epidermal thickening.
Reduced TSLP, IL-33, and CCL17 levels.
Significantly reduced skin infiltration of T cells, eosinophils, and neutrophils.
-
Animal Model:Flaky tail mice on a congenic C57BL/6J background[1]
-
Dosage:3 and 30 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice weekly for 6 weeks
-
Result:Significantly reduced skin inflammation score.
Reduced the number of mast cells and serum IgE levels.
Reduced the expression of IL-4, IL-17A, CCL17 and IFN-γ.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized Human IL-17c, His Tag can bind MOR-106. The EC50 for this effect is 7.102 ng/mL.
Chemical Information
-
CAS No. 2304625-87-2
-
Appearance Liquid
-
Molecular Weight 144.02 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
MOR12743; MOR03207
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Vandeghinste N, et al. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. J Invest Dermatol. 2018 Jul;138(7):1555-1563. [Content Brief]
[2]. Lauffer F, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020 Apr;34(4):800-809. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz